The Staby® technology from Delphi Genetics efficiently applied to DNA-Vaccine

Il y a 4 years

During the inauguration of its new building, the Belgian Biotech Company Delphi Genetics SA announced that the first antibiotic-free DNA vaccine using the Staby® technology was efficiently tested in vivo.

Together with academic and Biotech keyplayers, Delphi Genetics is participating to the DNAVAC project funded by the Walloon Region (BioWin project). The aim of the project is to develop and produce antibiotic-free DNA vaccines targeting veterinary diseases. As a model, the consortium developed a DNA vaccine against the Aujezsky virus the causative agent of pseudo-rabies.

“This virus was selected as it causes systematically an acute and lethal disease insusceptible species, thereby providing an excellent model to test the efficacy of a vaccinecandidate. The results of the challenge performed by Dr Anca Reschner are very clear:all vaccinated animals using the Staby® vectors were resistant to the lethal Aujeszkyvirus.” said Prof. Alain Vanderplasschen from the University of Liège (Immunology-
Vaccinology).